ABSTRACT
Bladder dysfunction due to neurologic diseases, the so-called neurogenic bladder (NB), is one of the most difficult problems in urology. The assessment and management of NB seems to vary markedly among countries. In many countries where selective anticholinergics are not yet available, other cheaper, nonselective drugs like oxyphencyclimine have been given as an alternative. Reports of augmentation cystoplasty for NB management have come from the largest countries of the developing world, like China, Mexico, Brazil, Iran, Pakistan, and India. Predictors of switching from clean intermittent catheterization to indwelling catheterization are refractory incontinence, dependence on caregivers, spasticity, and inexistence of adequate external collection device for women. Avoiding complications is the primary goal of surveillance and management in NB; however, the access to diagnostic modalities to follow NB patients is variable. There is a dearth of high-level evidence in the literature regarding international patterns of care in patients with NB.
